Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423851 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
A Phase 1 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by NS Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
- 9
- Study locations
NCT01423851: Completed Phase 1 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, sponsored by NS Pharma.
NCT01423851 is a Phase 1 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis that has completed, run by NS Pharma. The registered enrollment target is 77 participants, below the 118-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (35% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01423851, a Phase 1 study of Primary Myelofibrosis and Post-Essential Thrombocythemia Myelofibrosis, has completed, sponsored by NS Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)
Primary Outcome
AEs (non-serious, serious) as variables of safety and tolerability of NS-018 were assesed. The number of patients were presented as Overall summary of AEs including treatment-emergent AEs (TEAEs); Treatment-emergent SAEs; Drug-related TEAEs; Treatment-emergent AEs leading to permanent discontinuation of study drug; Hospitalization or prolongation of existing hospitalization; Death.
Conditions Studied
Interventions
- DRUG NS-018
Study Locations (9)
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Arizona
- Mayo Clinic Scottsdale Recruiting - Scottsdale
California
- UC San Diego Moores Cancer Center - San Diego
Florida
- Mayo Clinic, Jacksonville - Jacksonville
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Weill Cornell Medical College - New York
Texas
- MD Anderson Cancer Center, Department of Leukemia - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2011-06 |
| Est. Completion | 2020-04-22 |
| Phase | Phase 1 |
What the finished NCT01423851 record still lists
NCT01423851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 77 participants, a relatively small participant target, below the 118-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (35% lower).
The record links to 3 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which NS-018 is the first listed.
NCT01423851 lists 9 locations in 8 states (Illinois, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT01423851 about?
NCT01423851 is a clinical study titled "Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF". The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)
What is the current status of trial NCT01423851?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2011-06. Estimated completion is 2020-04-22.
What conditions does trial NCT01423851 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis.
What interventions are being tested in trial NCT01423851?
The interventions under investigation include: NS-018 (DRUG).
Who is sponsoring clinical trial NCT01423851?
This trial is sponsored by NS Pharma, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01423851 being conducted?
This trial has 9 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01423851's enrollment target sits among peer trials
77 10th of 30 higher than 21 of 30 other Primary Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
-
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 1
-
Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02127398 · 77 participants · Phase 2
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
- NCT04159103 · 77 participants · Phase 1
Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia
- NCT04683003 · 77 participants · Phase 3
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
- NCT05004116 · 77 participants · Phase 1
A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia